AKBA

Akebia Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality5/10
  • Growth↑ 5/10
  • Momentum↓ 1/10
Akebia Therapeutics sales and earnings growth
AKBA Growth
Neutral
  • Revenue Y/Y↑ 32.49%
  • EPS Y/Y↑ 65.22%
  • FCF Y/Y↑ 183.95%
Akebia Therapeutics gross and profit margin trends
AKBA Profitability
Good
  • Gross margin ↑ 79.00%
  • EPS margin↓ -7.10%
  • ROIC↓ 14.70%
Akebia Therapeutics net debt vs free cash flow
AKBA Risk
Great
  • Debt / Equity↓ 1.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 0.4

Akebia Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗